Viking Therapeutics Revives VK2735 Clinical Trials, Potential Market Rebound Ahead
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Fool
- Clinical Progress: Viking Therapeutics is advancing its VK2735 into phase 3 clinical trials, with strong phase 2 results for the GLP-1 obesity treatment indicating potential for significant stock price increases if successful, highlighting the company's prospects in the rapidly growing weight loss drug market.
- Market Challenges: Despite a stock price decline in 2025 due to profit-taking and high patient dropout rates for oral VK2735, the company is expected to regain investor confidence by addressing adverse reactions through dosage adjustments, which could facilitate a rebound.
- Animal Health Sector: Zoetis, a leader in the animal health industry, continues to show resilience despite regulatory challenges with its Librela and Solensia medications, effectively managing competition in dermatology to maintain growth momentum, underscoring its market strength.
- New Drug Approvals: Zoetis has received approval for Lenivia in Canada and Europe, a longer-acting treatment for osteoarthritis in dogs, which is expected to help the company overcome recent challenges and drive sales growth.
Analyst Views on VKTX
Wall Street analysts forecast VKTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VKTX is 97.27 USD with a low forecast of 70.00 USD and a high forecast of 125.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 35.320
Low
70.00
Averages
97.27
High
125.00
Current: 35.320
Low
70.00
Averages
97.27
High
125.00
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
